Handelsavisen
prelaunch
Companies Healthcare MTLF.TA
MT
MTLF.TA TASE (Tel Aviv) Biotechnology & Medical Research

Matricelf Ltd

$282,80
Open in Charts → Attach watcher ⌖
ILA
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
8,3B ILA
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Matricelf Ltd is a biotechnology company focused on healthcare diagnostics, developing and commercializing innovative diagnostic solutions for medical applications.

Business. Matricelf Ltd (MTLF.TA) is a biotechnology and medical research company focused on healthcare diagnostics. The firm is headquartered in Israel and is primarily listed on the Tel Aviv Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MTLF.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MTLF.TA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Matricelf Ltd (MTLF.TA) is a biotechnology and medical research company focused on healthcare diagnostics. The firm is headquartered in Israel and is primarily listed on the Tel Aviv Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Matricelf operates with a fully diluted share count of 29.24 million shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution pressure from stock options or convertible instruments. The company's market price of 278.8 ILS results in a market capitalization of approximately 8.15 billion ILS, but no liquidity metrics are available due to the absence of balance-sheet inputs and lack of going-concern language in source documents.

    Profitability and return metrics are not available for Matricelf, as the valuation snapshot does not include key financial ratios such as ROIC, EBITDA margins, or net profit margins. Without these metrics, it is not possible to compare the company's performance to industry benchmarks or cohort medians.

    The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown or geographic distribution is provided, making it difficult to assess the diversification of its revenue streams.

    Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or forward-looking revenue guidance for the current or next fiscal year. Historical revenue data is not included in the input, limiting the ability to assess growth trends.

    Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The company is flagged for potential liquidity risk, but no specific risk severities or composite risk scores are available.

    Recent events, including filings or transcripts, are not disclosed in the input data. No specific recent developments or disclosures are available to inform the company's current strategic or operational status.

    Key takeaways
    • Matricelf operates in the healthcare diagnostics segment with a focus on biotechnology.
    • The company has no immediate dilution pressure, as basic and diluted shares are equal.
    • No liquidity metrics are available, and liquidity risk could not be assessed.
    • Profitability and return metrics are not disclosed, limiting performance comparisons.
    • Revenue concentration and geographic exposure are not provided in the available data.
    • Growth trajectory and recent events are not disclosed, limiting forward-looking visibility.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $282,80
    Market cap
    $8.15B
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Matricelf Ltd Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MTLF.TACanonical
    TASE (Tel Aviv) · ILA

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage